Hope King1, Jian Xing1, Hazel D Dean2, Deborah Holtzman1. 1. Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Office of the Director, National Center for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND: Hepatitis B virus (HBV) infection can be prevented through vaccination. However, previous data show that only about 24%-45% of US adults at high risk of HBV infection are protected. Our aims were to assess prevalence and trends in protective levels of hepatitis B surface antibody (anti-HBs) from 2003 to 2014 and explore factors associated with protection among adults at high risk. METHODS: Data were taken from the 2003-2014 National Health and Nutrition Examination surveys. Our sample included adults aged 18-49 years who were tested for HBV and reported at least 1 of the following infection risks: history of sexually transmitted disease, sex with men (for men), infection with human immunodeficiency virus, and injection drug use. We calculated the prevalence of anti-HBs (≥10 mIU/mL), indicative of immunity from vaccination, among respondents for three 4-year time intervals (2003-2006, 2007-2010, and 2011-2014) and applied the Cochran-Mantel-Haenszel test to assess trends. Using multivariable logistic regression, we examined factors associated with positive anti-HBs serology. RESULTS: The prevalence of positive anti-HBs serology was 23.4%. Prevalence increased from 2003-2006 (16.3%) to 2007-2010 (27.3%), but no change occurred from 2007-2010 (27.3%) to 2011-2014 (28.1%). Among factors predicting positive anti-HBs serology were young age and higher education. CONCLUSIONS: By 2014, less than one-third of adults aged 18-49 years at risk of infection exhibited protective antibodies ≥10 mIU/mL. Because these adults account for a majority of unprotected adults, targeted intervention strategies are essential to achieve the hepatitis B elimination goal. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND:Hepatitis B virus (HBV) infection can be prevented through vaccination. However, previous data show that only about 24%-45% of US adults at high risk of HBV infection are protected. Our aims were to assess prevalence and trends in protective levels of hepatitis B surface antibody (anti-HBs) from 2003 to 2014 and explore factors associated with protection among adults at high risk. METHODS: Data were taken from the 2003-2014 National Health and Nutrition Examination surveys. Our sample included adults aged 18-49 years who were tested for HBV and reported at least 1 of the following infection risks: history of sexually transmitted disease, sex with men (for men), infection with human immunodeficiency virus, and injection drug use. We calculated the prevalence of anti-HBs (≥10 mIU/mL), indicative of immunity from vaccination, among respondents for three 4-year time intervals (2003-2006, 2007-2010, and 2011-2014) and applied the Cochran-Mantel-Haenszel test to assess trends. Using multivariable logistic regression, we examined factors associated with positive anti-HBs serology. RESULTS: The prevalence of positive anti-HBs serology was 23.4%. Prevalence increased from 2003-2006 (16.3%) to 2007-2010 (27.3%), but no change occurred from 2007-2010 (27.3%) to 2011-2014 (28.1%). Among factors predicting positive anti-HBs serology were young age and higher education. CONCLUSIONS: By 2014, less than one-third of adults aged 18-49 years at risk of infection exhibited protective antibodies ≥10 mIU/mL. Because these adults account for a majority of unprotected adults, targeted intervention strategies are essential to achieve the hepatitis B elimination goal. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Entities:
Keywords:
National Health and Nutrition Examination Survey; United States; hepatitis B; hepatitis B vaccination; hepatitis B virus (HBV) infection
Authors: Sarah Schillie; Tanja Walker; Steven Veselsky; Susan Crowley; Cristina Dusek; Julie Lazaroff; Sandra A Morris; Kenneth Onye; Stephen Ko; Nancy Fenlon; Noele P Nelson; Trudy V Murphy Journal: Pediatrics Date: 2015-04-20 Impact factor: 7.124
Authors: C Cohen; S D Holmberg; B J McMahon; J M Block; C L Brosgart; R G Gish; W T London; T M Block Journal: J Viral Hepat Date: 2010-12-08 Impact factor: 3.728
Authors: Holly A Hill; Laurie D Elam-Evans; David Yankey; James A Singleton; Yoonjae Kang Journal: MMWR Morb Mortal Wkly Rep Date: 2017-11-03 Impact factor: 17.586